Steven J. Gamblin

Steven J. Gamblin

Auto-generated profile, based on publicly available information

Steven J. Gamblin

Structural Biology of Disease Processes Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1997 in Cell
Verified
Journal Article
Closed access
MYMichael B Yaffe
Michael B Yaffe
KRKatrin Rittinger
Katrin Rittinger
Stefano VoliniaStefano Volinia
Stefano Volinia
PCPaul R Caron
Paul R Caron
AAAlastair Aitken
Alastair Aitken
LCLewis C. Cantley
Lewis C. Cantley

20 September 2009 in Nature
Verified
Journal Article
Closed access
PDF file
RMRaphael Margueron
Raphael Margueron
NJNeil Justin
Neil Justin
KOKatsuhito Ohno
Katsuhito Ohno
MSMiriam L. Sharpe
Miriam L. Sharpe
JSJinsook Son
Jinsook Son
SGSteven J. Gamblin
Steven J. Gamblin

17 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DBDonald J. Benton
Donald J. Benton
AWAntoni G. Wrobel
Antoni G. Wrobel
PXPengqi Xu
Pengqi Xu
CRChloë Roustan
Chloë Roustan
SMStephen R. Martin
Stephen R. Martin
SGSteven J. Gamblin
Steven J. Gamblin

13 March 2011 in Nature
Verified
Journal Article
Open access
PDF file
BXBing Xiao
Bing Xiao
MSMatthew J. Sanders
Matthew J. Sanders
EUElizabeth Underwood
Elizabeth Underwood
RHRichard Heath
Richard Heath
FMFaith V. Mayer
Faith V. Mayer
SGSteven J. Gamblin
Steven J. Gamblin
AMP-activated protein kinase (AMPK) has an important role in regulating cellular energy metabolism; in response to a fall in intracellular ATP levels, it activates energy-producing pathways and inhibits energy-consuming processes. Here, a role for ADP in regulating AMPK by protecting the enzyme from dephosphorylation is defined, and a crystal structure of the active enzyme containing the kinase domain is presented. A model is proposed for how AMP and ADP regulate AMPK activity. The heterotrimeric AMP-activated protein kinase (AMPK) has a key role in regulating cellular energy metabolism; in response to a fall in intracellular ATP levels it activates energy-producing pathways and inhibits energy-consuming processes1. AMPK has been implicated in a number of diseases related to energy metabolism including type 2 diabetes, obesity and, most recently, cancer2,3,4,5,6. AMPK is converted from an inactive form to a catalytically competent form by phosphorylation of the activation loop within the kinase domain7: AMP binding to the γ-regulatory domain promotes phosphorylation by the upstream kinase8, protects the enzyme against dephosphorylation, as well as causing allosteric activation9. Here we show that ADP binding to just one of the two exchangeable AXP (AMP/ADP/ATP) binding sites on the regulatory domain protects the enzyme from dephosphorylation, although it does not lead to allosteric activation. Our studies show that active mammalian AMPK displays significantly tighter binding to ADP than to Mg-ATP, explaining how the enzyme is regulated under physiological conditions where the concentration of Mg-ATP is higher than that of ADP and much higher than that of AMP. We have determined the crystal structure of an active AMPK complex. The structure shows how the activation loop of the kinase domain is stabilized by the regulatory domain and how the kinase linker region interacts with the regulatory nucleotide-binding site that mediates protection against dephosphorylation. From our biochemical and structural data we develop a model for how the energy status of a cell regulates AMPK activity.

11 December 2020 in Science
Verified
Journal Article
Open access
PDF file
KNKevin W. Ng
Kevin W. Ng
NFNikhil Faulkner
Nikhil Faulkner
GCGeorgina H. Cornish
Georgina H. Cornish
ARAnnachiara Rosa
Annachiara Rosa
RHRuth Harvey
Ruth Harvey
GKGeorge Kassiotis
George Kassiotis
Antibodies predating infection: Immunological memory after infection with seasonal human coronaviruses (hCoVs) may potentially contribute to cross-protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ng et al. report that in a cohort of 350 SARS-CoV-2–uninfected individuals, a small proportion had circulating immunoglobulin G (IgG) antibodies that could cross-react with the S2 subunit of the SARS-CoV-2 spike protein (see the Perspective by Guthmiller and Wilson). By contrast, COVID-19 patients generated IgA, IgG, and IgM antibodies that recognized both the S1 and S2 subunits. The anti-S2 antibodies from SARS-CoV-2–uninfected patients showed specific neutralizing activity against both SARS-CoV-2 and SARS-CoV-2 S pseudotypes. A much higher percentage of SARS-CoV-2–uninfected children and adolescents were positive for these antibodies compared with adults. This pattern may be due to the fact that children and adolescents generally have higher hCoV infection rates and a more diverse antibody repertoire, which may explain the age distribution of COVID-19 susceptibility. Science , this issue p. 1339 ; see also p. 1272

3 November 2004 in Nature
Verified
Journal Article
Closed access
PDF file
SCSergei Chuikov
Sergei Chuikov
JKJulia K. Kurash
Julia K. Kurash
JWJonathan R. Wilson
Jonathan R. Wilson
BXBing Xiao
Bing Xiao
NJNeil Justin
Neil Justin
DRDanny Reinberg
Danny Reinberg